Patents by Inventor Kenneth Luehrsen

Kenneth Luehrsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-Siglec-7 antibodies for the treatment of cancer
    Patent number: 11773162
    Abstract: The invention provides methods and compositions for the treatment of cancer using anti-Siglec7 antibodies.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: October 3, 2023
    Assignee: Allakos, Inc.
    Inventors: Christopher Bebbington, Wouter Korver, Nenad Tomasevic, Suzy El Bader, Kenneth Luehrsen
  • ANTI-SIGLEC-7 ANTIBODIES FOR THE TREATMENT OF CANCER
    Publication number: 20190194323
    Abstract: The invention provides methods and compositions for the treatment of cancer using anti-Siglec7 antibodies.
    Type: Application
    Filed: August 4, 2017
    Publication date: June 27, 2019
    Inventors: Christopher Bebbington, Wouter Korver, Nenad Tomasevic, Suzy El Bader, Kenneth Luehrsen
  • Antibodies to EphA3
    Patent number: 9290571
    Abstract: The current invention relates to high-affinity antibodies to EphA3 that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.
    Type: Grant
    Filed: December 30, 2013
    Date of Patent: March 22, 2016
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Kenneth Luehrsen, David Martinez, Christina Yi, Christopher R. Bebbington, Geoffrey T. Yarranton
  • ANTIBODIES TO GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR
    Publication number: 20150344565
    Abstract: The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.
    Type: Application
    Filed: April 2, 2015
    Publication date: December 3, 2015
    Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton
  • Anti-EMR1 antibodies
    Patent number: 9045539
    Abstract: The invention provides anti-EGF-like module containing, mucin-like, hormone receptor-like 1 (EMR1) antibodies and methods of using such antibodies to treat EMR1-related diseases.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: June 2, 2015
    Assignee: Kalobios Pharmaceuticals, Inc.
    Inventors: Kenneth Luehrsen, Mark Baer, Christopher R. Bebbington, David Martinez, Varghese Palath, Swathi Sujatha-Bhaskar, Nenad Tomasevic, Jason Williams, Geoffrey T. Yarranton
  • Antibodies to granulocyte-macrophage colony-stimulating factor
    Patent number: 9017674
    Abstract: The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: April 28, 2015
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey Yarranton
  • ANTIBODIES TO THE PCRV ANTIGEN OF PSEUDOMONAS AERUGINOSA
    Publication number: 20150030614
    Abstract: The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.
    Type: Application
    Filed: October 8, 2014
    Publication date: January 29, 2015
    Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton, Mark Baer
  • Antibodies to the PcrV antigen of
    Patent number: 8877191
    Abstract: The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.
    Type: Grant
    Filed: October 11, 2011
    Date of Patent: November 4, 2014
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton, Mark Baer
  • Antibodies to EphA3
    Publication number: 20140120114
    Abstract: The current invention relates to high-affinity antibodies to EphA3 that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.
    Type: Application
    Filed: December 30, 2013
    Publication date: May 1, 2014
    Applicant: KALOBIOS PHARMACEUTICALS, INC.
    Inventors: Kenneth Luehrsen, David Martinez, Christina Yi, Christopher R. Bebbington, Geoffrey T. Yarranton
  • Antibodies to EphA3
    Patent number: 8664365
    Abstract: The current invention relates to high-affinity antibodies to EphA3 that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: March 4, 2014
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Kenneth Luehrsen, David Martinez, Christina Yi, Christopher R. Bebbington, Geoffrey T. Yarranton
  • ANTI-EMR1 ANTIBODIES
    Publication number: 20130064826
    Abstract: The invention provides anti-EMR1 antibodies and methods of using such antibodies to treat EMR1-related diseases.
    Type: Application
    Filed: May 25, 2012
    Publication date: March 14, 2013
    Inventors: Kenneth Luehrsen, Mark Baer, Christopher R. Bebbington, David Martinez, Varghese Palath, Swathi Sujatha-Bhaskar, Nenad Tomasevic, Jason Williams, Geoffrey T. Yarranton
  • ANTIBODIES TO GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR
    Publication number: 20120213776
    Abstract: The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.
    Type: Application
    Filed: April 30, 2012
    Publication date: August 23, 2012
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton
  • Antibodies to granulocyte-macrophage colony-stimulating factor
    Patent number: 8168183
    Abstract: The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.
    Type: Grant
    Filed: April 28, 2009
    Date of Patent: May 1, 2012
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton
  • Antibodies to the PcrV Antigen of Pseudomonas aeruginosa
    Publication number: 20120020986
    Abstract: The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.
    Type: Application
    Filed: October 11, 2011
    Publication date: January 26, 2012
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton, Mark Baer
  • Antibodies to the PcrV antigen of
    Patent number: 8044181
    Abstract: The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.
    Type: Grant
    Filed: December 1, 2008
    Date of Patent: October 25, 2011
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton, Mark Baer
  • GENERATION OF ANTIBODIES TO AN EPITOPE OF INTEREST
    Publication number: 20110245100
    Abstract: The invention provides methods of obtaining antibodies to an epitope of interest based on an anti-hapten focused library.
    Type: Application
    Filed: April 4, 2011
    Publication date: October 6, 2011
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Geoffrey T. Yarranton, Kenneth Luehrsen, Christopher R. Bebbington, Nenad Tomasevic
  • Antibody specificity transfer using minimal essential binding determinants
    Patent number: 7981843
    Abstract: The present invention provides methods of making antibodies having the binding specificity of a reference antibody. Antibodies generated by the methods of the inventions have at least one minimal essential binding specificity determinant from a heavy chain or light chain CDR3 from the reference antibody. The method can be used, e.g., in humanization procedures. The invention also provides libraries and antibodies made in accordance with the methods.
    Type: Grant
    Filed: January 20, 2005
    Date of Patent: July 19, 2011
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Peter Flynn, Kenneth Luehrsen, Robert F. Balint, Jeng-Horng Her, Christopher R. Bebbington, Geoffrey T. Yarranton
  • Antibodies to EphA3
    Publication number: 20110123549
    Abstract: The current invention relates to high-affinity antibodies to EphA3 that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.
    Type: Application
    Filed: October 14, 2010
    Publication date: May 26, 2011
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Kenneth Luehrsen, David Martinez, Christina Yi, Christopher R. Bebbington, Geoffrey T. Yarranton
  • ANTIBODIES TO GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR
    Publication number: 20090274706
    Abstract: The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.
    Type: Application
    Filed: April 28, 2009
    Publication date: November 5, 2009
    Applicant: Kalobios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton
  • Antibodies to the PcrV Antigen of Pseudomonas aeruginosa
    Publication number: 20090191186
    Abstract: The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.
    Type: Application
    Filed: December 1, 2008
    Publication date: July 30, 2009
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton, Mark Baer